EUVIMEDExplore EUVIMED
BeobachtungsstudieOpen access · CC BY-NC-ND 4.0

Insights into cancer characteristics among SARS-CoV-2 infected hospitalized patients: a comprehensive analysis from the National Clinical Registry for COVID-19

Soumyadip Chatterji, Alka Turuk, Parijat Das, Sanjay Bhattacharya, Sudipta Mukherjee, Pralay Shankar Ghosh, Argha Chatterjee, Aparna Mukerjee, Gunjan Kumar, Aanchal Satija, Kripa Josten, Ashish Bhalla and 11 more

Journal of Cancer Research and Clinical Oncology · 2024

DOI: 10.1007/s00432-024-05966-1 ↗

At a glance

Beobachtungsstudie in Journal of Cancer Research and Clinical Oncology, 2024. Written by Soumyadip Chatterji and 22 co-authors. Institution: Department of Infectious Disease, Tata Medical Centre, Kolkata, India. Major MEDLINE topics: COVID-19, Neoplasms, Registries, SARS-CoV-2. 39 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Indian Council of Medical Research.

AbstractSubjectsBibliographic detailsCiteRelated studies

Abstract (original language)

PURPOSE: Cancer outcome is dependent on multiple predetermining factors including cancer, type of cancer and its related factors. This study aims to investigate the association between COVID-19 & cancer/cancer types, focusing on risk of in-hospital mortality within 30 days of hospitalization of COVID-19 patients with cancer. MATERIALS AND METHODS: We did a registry (National Clinical Registry for COVID-19) based retrospective observational study including 51,544 patients, of whom 976 were patients with cancer, admitted with COVID-19 between August 2020 and August 2023 across 42 hospitals of India. RESULTS: Out of 51,544 patients, 976 (1.8%) had cancer. Hematological malignancies made up 15.06% (147 cases), while solid cancers accounted for 29.5% (288 cases), with genitourinary (18.4%, 80 cases), gastrointestinal (15.2%, 49 cases), and lung cancers (10.1%, 34 cases) being the most common. Solid cancers had the highest in-hospital mortality rate at 25%. Survival analysis showed that cancer-related hazards were highest at admission but decreased to levels comparable with other morbidities within nine to ten days. For each cancer type, the hazard was significantly elevated compared to that of the cancer-free (Other Comorbidities and No Comorbiditiy) groups during the initial period of hospitalization. The use of Remdesivir, steroids, and anticoagulants reduced mortality risk, and prior COVID-19 vaccination was protective against mortality across all cancer types. CONCLUSION: This study shows that both cancer in general and specific cancer types significantly increase the risk of severe outcomes among SARS-CoV-2-infected patients, especially immediately after hospitalization. The findings highlight the need for close monitoring and personalized interventions for COVID-19 patients with cancer for at least 10 days post-hospitalization, with a more specific high-risk period ranging from 7 to 18 days depending on the type of cancer.

Subjects

MeSH terms (MEDLINE)

COVID-19NeoplasmsRegistriesSARS-CoV-2Hospital MortalityHospitalizationHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultIndiaComorbidityYoung AdultAged, 80 and overPandemics

Author keywords

COVID-19CancerICUSARS-CoV-2Vaccine

Authors and institutions

  • Department of Infectious Disease, Tata Medical Centre, Kolkata, India.
  • Clinical Studies, and Trials Unit, Division of Developmental Research, Indian Council of Medical Research, New Delhi, India.
  • Department of Microbiology, Tata Medical Centre, 14 Major Arterial Road (E-W), Newtown, Kolkata, 700160, India. parijat.das@tmckolkata.com.
  • Department of Microbiology, Tata Medical Centre, 14 Major Arterial Road (E-W), Newtown, Kolkata, 700160, India.
  • Department of Critical Care Medicine, Tata Medical Centre, Kolkata, India.
  • Department of Radiology, Tata Medical Centre, Kolkata, India.

Funding

  • Indian Council of Medical Research

Cite

APA

Chatterji, S., Turuk, A., Das, P., Bhattacharya, S., Mukherjee, S., Ghosh, P. S., Chatterjee, A., Mukerjee, A., Kumar, G., Satija, A., Josten, K., Bhalla, A., Malhotra, P., Bhuniya, S., Talukdar, A., Ghosh, S., Misra, S., Bhardwaj, P., Chatterjee, S., …, & National Clinical Registry for COVID Team (2024). Insights into cancer characteristics among SARS-CoV-2 infected hospitalized patients: a comprehensive analysis from the National Clinical Registry for COVID-19. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05966-1

Vancouver

Chatterji S, Turuk A, Das P, Bhattacharya S, Mukherjee S, Ghosh PS, et al. Insights into cancer characteristics among SARS-CoV-2 infected hospitalized patients: a comprehensive analysis from the National Clinical Registry for COVID-19. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-05966-1

BibTeX
@article{Chatterji2024,
  author = {Chatterji, Soumyadip and Turuk, Alka and Das, Parijat and Bhattacharya, Sanjay and Mukherjee, Sudipta and Ghosh, Pralay Shankar and Chatterjee, Argha and Mukerjee, Aparna and Kumar, Gunjan and Satija, Aanchal and Josten, Kripa and Bhalla, Ashish and Malhotra, Pankaj and Bhuniya, Sourin and Talukdar, Arunansu and Ghosh, Soumitra and Misra, Sanjeev and Bhardwaj, Pankaj and Chatterjee, Subhranga and Menon, Geetha R and Deo, Vishal and Rao, Vishnu Vardhan and National Clinical Registry for COVID Team, National Clinical Registry for COVID Team},
  title = {Insights into cancer characteristics among SARS-CoV-2 infected hospitalized patients: a comprehensive analysis from the National Clinical Registry for COVID-19},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2024},
  doi = {10.1007/s00432-024-05966-1}
}
Start for free →